Immune mechanism of aplastic anemia

International Journal of Hematology

Volumn 66, Issue 2, 1997, Pages 127-134

  Nakao, Shinji ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Aplastic anemia; HLA DRB1*1501; T cell clone; T cell clonotype

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; CYCLOSPORIN A; HLA DR ANTIGEN;

APLASTIC ANEMIA; BONE MARROW CELL; BONE MARROW HYPOPLASIA; DISEASE ASSOCIATION; HLA SYSTEM; HUMAN; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0031214725     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00032-7     Document Type: Review

References (26)

1. Young NS, Alter BP. Pathophysiology II: Immune suppression of hematopoiesis. Aplastic Anemia Acquired and Inherited. Philadelphia, PA: Sanders, 1994:68-99.
2. Mathé G., Amiel J.L., Schwarzenberg L.et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 2:1970;131-136.
3. Champlin R., Ho W., Gale R.P. Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. N Engl J Med. 308:1983;113-118.
4. Schrezenmeier H., Schlander M., Raghavachar A. Cyclosporin A in aplastic anemia-report of a workshop. Ann Hematol. 65:1992;33-36.
5. Gluckman E., Esperou B.H., Baruchel A.et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 79:1992;2540-2546.
6. Frickhofen N., Kaltwasser J.P., Schrezenmeier H.et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 324:1991;1297-1304.
7. Rosenfeld S.J., Kimball J., Vining D., Young N.S. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 85:1995;3058-3065.
8. Bacigalupo A., Broccia G., Corda G.et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood. 85:1995;1348-1353.
9. Champlin R.E., Feig S.A., Sparkes R.S., Gale R.P. Bone marrow transplantation from identical twins in the treatment of aplastic anemia: Implication for the pathogenesis of the disease. Br J Haematol. 56:1984;455-463.
10. Zoumbos N.C., Gascon P., Djeu J.Y., Young N.S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA. 82:1985;188-192.
11. Hinterberger W., Adolf G., Aichinger G.et al. Further evidence for lymphokine overproduction in severe aplastic anemia. Blood. 72:1988;266-272.
12. Nakao S., Yamaguchi M., Shiobara S.et al. Interferon-γ gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 79:1992;2532-2535.
13. + cells of patients with aplastic anaemia. Br J Haematol. 91:1995;245-252.
14. Shevach E.M. The effects of cyclosporin A on the immune system. Annu Rev Immunol. 3:1985;397-423.
15. Chapuis B., Von Fliedner V.E., Jeannet M.et al. Increased frequency of DR2 in patients with aplastic anemia and increased DR sharing in their parents. Br J Hematol. 63:1986;51-57.
16. Nakao S, Takamatsu H, Chuhjo T, Matsuda T. HLA-DRB1 alleles of patients with aplastic anemia and response to immunosuppressive therapy. Ann. Rep. Intractable Hemopoietic Disease Res. Group 1994;108 (in Japanese).
17. Nimer S.D., Ireland P., Meshikinpour A.P.et al. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 84:1994;923-927.
18. Ragman F.P., Ashby D., Davies J.M. Does HLA-DR predict response to specific immunosuppressive therapy in aplastic anemia? Br J Haematol. 74:1990;545-546.
19. Nakao S., Yamaguchi M., Yasue S., Shiobara S., Saito M., Matsuda T. HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol. 40:1992;239-240.
20. Nakao S., Takamatsu H., Chuhjo T.et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 84:1994;4257-4261.
21. Pannetier C., Even J., Kourilsky P. T-cell repertoire and clonal expansions in normal and clinical samples. Immunol Today. 16:1995;176-181.
22. Yamamoto K., Sakoda H., Nakajima T.et al. Accumulation of multiple T-cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol. 4:1992;1219-1223.
23. Takamatsu H., Nakao S., Yamaguchi M.et al. Analysis of the T-cell clonotype in the bone marrow of immune-mediated aplastic anemia: Identification of a T-cell clone that preferentially proliferates in the bone marrow of a cyclosporine-dependent aplastic anemia patient. Blood. 84:1994;9a.
24. + T-cells in a patient with aplastic anemia. J Clin Invest. 87:1991;1567-1574.
25. + T-cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia. Exp Hematol. 23:1995;433-438.
26. Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood, in press.